MORBIDITY

Sarcopenia in Ageing and Chronic Illness: Trial Endpoints and Regulatory Issues.

In December 2024, the Society on Cachexia and Wasting Disorders (SCWD) hosted a Regulatory and Trial Update Workshop in Washington, D.C., bringing together experts from academia, industry, and the US Food and Drug Administration (FDA). This article summarizes key topics...

๐Ÿ—“๏ธ 2025-06-01
๐Ÿ“ฐ Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreSarcopenia in Ageing and Chronic Illness: Trial Endpoints and Regulatory Issues.

Prediction Models for Risk of Cardiorespiratory Morbidity/Mortality and Fracture Among Young Adults With Cerebral Palsy.

There is a dearth of screening tools for cardiorespiratory disease and fracture risk, such as risk prediction models, for adults with cerebral palsy (CP). There is heterogeneity of pathophysiology related to the severity of CP and aging, such that a...

๐Ÿ—“๏ธ 2025-02-01
๐Ÿ“ฐ Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MorePrediction Models for Risk of Cardiorespiratory Morbidity/Mortality and Fracture Among Young Adults With Cerebral Palsy.

Body composition derangements in lung cancer patients treated with first-line pembrolizumab: A multicentre observational study.

While immune checkpoint inhibitors (ICIs) are increasingly reshaping the therapeutic landscape of non-small-cell lung cancer (NSCLC), only a limited proportion of patients achieve a relevant and long-lasting benefit with these treatments, calling for the identification of clinical and, ideally modifiable,...

๐Ÿ—“๏ธ 2024-10-22
๐Ÿ“ฐ Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreBody composition derangements in lung cancer patients treated with first-line pembrolizumab: A multicentre observational study.

Efficacy of empagliflozin in heart failure with preserved ejection fraction according to frailty status in EMPEROR-Preserved.

Frailty is a severe, common co-morbidity associated with heart failure (HF) with preserved ejection fraction (HFpEF). The impact of frailty on HFpEF outcomes may affect treatment choices in HFpEF. The impact of frailty on HFpEF patients and any impact on...

๐Ÿ—“๏ธ 2023-12-29
๐Ÿ“ฐ Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreEfficacy of empagliflozin in heart failure with preserved ejection fraction according to frailty status in EMPEROR-Preserved.

Subscribe to the SCWD Newsletter

Stay Informed with the Latest Updates and Exclusive Insights!